GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Short-Term Capital Lease Obligation

Kyverna Therapeutics (Kyverna Therapeutics) Short-Term Capital Lease Obligation : $3.72 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Short-Term Capital Lease Obligation?

Kyverna Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.72 Mil.

Kyverna Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 ($2.80 Mil) to Dec. 2023 ($2.92 Mil) and increased from Dec. 2023 ($2.92 Mil) to Mar. 2024 ($3.72 Mil).

Kyverna Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.81 Mil) to Dec. 2022 ($2.28 Mil) and increased from Dec. 2022 ($2.28 Mil) to Dec. 2023 ($2.92 Mil).

Kyverna Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Kyverna Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Short-Term Capital Lease Obligation Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Capital Lease Obligation
0.81 2.28 2.92

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Short-Term Capital Lease Obligation Get a 7-Day Free Trial 2.28 - 2.80 2.92 3.72

Kyverna Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Kyverna Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Short-Term Capital Lease Obligation
Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Website
https://www.kyvernatx.com
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024